Patients with HIV infection are more likely to develop anogenital warts compared to HIV-negative people and are susceptible to treatment failures and recurrences. We report a case of extensive vulvar warts in an HIV-positive woman successfully treated with sinecatechins ointment. After the failure of a combination of cryotherapy and imiquimod 5% cream, we started therapy with sinecatechins 10% ointment. The patient developed an intense local inflammatory reaction after three weeks that induced the discontinuation of the therapy. After two weeks, we observed a complete regression of inflammation and a reduction of genital warts. The lesions completely regressed within a few weeks, with no relapse after eight months. Sinecatechins is a standardized extract of green tea leaves, effective in the treatment of external genital and perianal warts in immunocompetent patients, but their role has not been yet studied for immunocompromised people. Our case may represent a starting point for further studies, in order to evaluate the relation between treatment dosage, side effects, and drug response in immunocompromised patients.
DolevJCMaurerTSpringerGet al.
Incidence and risk factors for verrucae in women. AIDS2008;
22: 1213–1219.
2.
SilverbergMJAhdiehLMunozAet al.
The impact of HIV infection and immunodeficiency on human papillomavirus type 6 or 11 infection and on genital warts. Sex Transm Dis2002;
29: 427–435.
3.
De PanfilisGMelzaniGMoriGet al.
Relapses after treatment of external genital warts are more frequent in HIV-positive patients than in HIV-negative controls. Sex Transm Dis2002;
29: 121–125.
4.
ConleyLJEllerbrockTVBushTJet al.
HIV-1 infection and risk of vulvovaginal and perianal condylomata acuminata and intraepithelial neoplasia: a prospective cohort study. Lancet2002;
359: 108–113.
5.
RosenT.Green tea catechins: biologic properties, proposed mechanisms of action, and clinical implications. J Drugs Dermatol2012;
11: e55–e60.
6.
StockflethEBetiHOrasanRet al.
Topical Polyphenon E in the treatment of external genital and perianal warts: a randomized controlled trial. Br J Dermatol2008;
158: 1329–1338.
TattiSSwinehartJMThielertCet al.
Sinecatechins, a defined green tea extract, in the treatment of external anogenital warts: a randomized controlled trial. Obstet Gynecol2008;
111: 1371–1379.
9.
GrossGMeyerKGPresHet al.
A randomized, double-blind, four-arm parallel-group, placebo-controlled Phase II/III study to investigate the clinical efficacy of two galenic formulations of Polyphenon E in the treatment of external genital warts. J Eur Acad Dermatol Venerol2007;
21: 1404–1412. Nov
10.
TattiSStockflethEBeutnerKRet al.
Polyphenon E: a new treatment for external anogenital warts. Br J Dermatol2010;
162: 176–184.
11.
NguyenHPDoanHQBrunellDJet al.
Apoptotic gene expression in sinecatechins-treated external genital and perianal warts. Viral Immunol2014;
27: 556–558.
12.
KhanNAfaqFSaleemMet al.
Targeting multiple signaling pathways by green tea polyphenol (-)-epigallocatechin-3-gallate. Cancer Res2006;
66: 2500–2505.
13.
StockflethEMeyerT.The use of sinecatechins (polyphenon E) ointment for treatment of external genital warts. Expert Opin Biol Ther2012;
12: 783–793.
14.
TrompezinskiSDenisASchmittDet al.
Comparative effects of polyphenols from green tea (EGCG) and soybean (genistein) on VEGF and IL-8 release from normal human keratinocytes stimulated with the proinflammatory cytokine TNF alpha. Arch Dermatol Res2003;
295: 112–116.
15.
TyringSK.Sinecatechins: effects on HPV-induced enzymes involved in inflammatory mediator generation. J Clin Aesthet Dermatol2012;
5: 19–26.
16.
MassadLSXieXDarraghTet al.
Genital warts and vulvar intraepithelial neoplasia: natural history and effects of treatment and human immunodeficiency virus infection. Obstet Gynecol2011;
118: 831–839.
17.
RatnamIChiuCKandalaNBet al.
Incidence and risk factors for immune reconstitution inflammatory syndrome in an ethnically diverse HIV type 1-infected cohort. Clin Infect Dis2006;
42: 418–427.
18.
IarikovDDukeWSkiestD.Extensive development of flat warts as a cutaneous manifestation of immune reconstitution syndrome. AIDS Read2008;
18: 524–527.
19.
LehloenyaRJToddGWallaceJet al.
Diagnostic patch testing following tuberculosis-associated cutaneous adverse drug reactions induces systemic reactions in HIV-infected persons. Br J Dermatol2016;
175: 150–156.
20.
SmithKJSkeltonHGYeagerJet al.
Increased drug reactions in HIV-1-positive patients: a possible explanation based on patterns of immune dysregulation seen in HIV-1 disease. Clin Exp Dermatol1997;
22: 118–123.
21.
YunihastutiEWidhaniAKarjadiTH.Drug hypersensitivity in human immunodeficiency virus-infected patient: challenging diagnosis and management. Asia Pac Allergy2014;
4: 54–67.
22.
GilsonRJShupackJLFriedman-KienAEet al.
A randomized, controlled, safety study using imiquimod for the topical treatment of anogenital warts in HIV-infected patients. Imiquimod Study Group. AIDS1999;
13: 2397–2404.
23.
WernerRNWestfechtelLDresslerCet al.
Anogenital warts and other HPV-associated anogenital lesions in the HIV-positive patient: a systematic review and meta-analysis of the efficacy and safety of interventions assessed in controlled clinical trials. Sex Transm Infect2017;
93: 543–550.
24.
GrandolfoMMilaniM.Efficacy and tolerability of polyphenon E in “difficult-to-treat” multiple genital warts in an HIV-positive male subject. Case Rep Dermatol2017;
9: 55–59.
25.
JuhlMESeferovicVAntonijevicSet al.
Combined treatment of anogenital HPV infection with cryodestruction, podophyllin 25% and post-ablation immunomodulation with sinecatechins 15% ointment – retrospective analysis. Int J STD AIDS2016;
27: 1071–1078.
26.
OnSCLinknerRVHaddicanMet al.
A single-blinded randomized controlled study to assess the efficacy of twice daily application of sinecatechins 15% ointment when used sequentially with cryotherapy in the treatment of external genital warts. J Drugs Dermatol2014;
13: 1400–1405.
